LabGenomics Acquires Kels, an In Vitro Diagnostic Company, Shares Worth 2 Billion KRW

[Asia Economy Reporter Minwoo Lee] LabGenomics announced on the 1st that it has decided to acquire 134,680 shares of Kels, a research and development company of in vitro diagnostic devices, worth approximately 2 billion KRW. The company explained, "This is a strategic investment to establish growth momentum through business diversification and to supply immune diagnostic kits."